Vascular cell adhesion protein 1 also known as vascular cell adhesion molecule 1 (VCAM-1) or cluster of differentiation 106 (CD106) is a protein that in humans is encoded by the VCAM1 gene. [5] VCAM-1 functions as a cell adhesion molecule.

Dec 25, 2024 · VCAM1 (Vascular Cell Adhesion Molecule 1) is a Protein Coding gene. Diseases associated with VCAM1 include Viral Encephalitis and Chronic Venous Insufficiency. Among its related pathways are Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling and Cytokine Signaling in Immune system.

VCAM-1 was originally identified as a cell adhesion molecule that helps regulate inflammation-associated vascular adhesion and the transendothelial migration of leukocytes, such as macrophages and T cells.

Aug 1, 2023 · ICAM-1 and VCAM-1 regulates firm attachment and transmigration of leukocytes to endothelial cells in inflammatory conditions. ICAM-1 & VCAM-1 facilitates occurrence of cardiac events by regulating leukocyte infiltration, recruitment and endothelial cell proliferation.

Mar 7, 2022 · A new study by Pinho et al. identifies the adhesion molecule VCAM1 as an immune checkpoint that protects haematopoietic stem and progenitor cells, as well as leukaemic cells, from monocytic...

VCAM-1 expression is upregulated by CD34+/CD133+-stem cells derived from septic patients; Circulating soluble vascular cell adhesion molecule (VCAM-1) level was a useful diagnostic parameter for understanding the difference between coronary artery disease (CAD) and cardiac syndrome X (CSX).

May 13, 2023 · We found that VCAM-1 via JunB regulates IL-8 promoter activity and expression in human retinal endothelial cells. In addition, our study outlines the regulatory role of VCAM-1-JunB-IL-8...

Nov 19, 2018 · We identify a VCAM-1+ macrophage-like niche cell population that patrols the inner surface of the venous plexus, interacts with HSPCs in an ITGA4-dependent manner, and directs HSPC...

Apr 2, 2018 · This review covers the role and relevance of VCAM-1 in inflammation, and also highlights the emerging potential of VCAM-1 as a novel therapeutic target in immunological disorders and cancer.

In AML, VCAM1 promotes disease progression, whereas VCAM1 inhibition or deletion reduces leukaemia burden and extends survival. These results suggest that VCAM1 engagement regulates a critical immune-checkpoint gate in the bone marrow, and offers an alternative strategy to eliminate cancer cells via modulation of the innate immune tolerance.